Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tara Rower

Nurse Practitioner Beavercreek, OH Nurse Practitioner

NPI 1215237961 CMS profile 11124812

3572 Dayton Xenia Rd, Beavercreek, OH 45432

Open in the dashboard

General payments

$16,306

1,032 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tara Rower of Beavercreek, OH is reported in the CMS Open Payments database as having received $16,306 across 1,032 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,440 203
2024 General $4,083 253
2023 General $3,720 254
2022 General $2,566 174
2021 General $2,498 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tara Rower
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tara Rower were reported at $3,440. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tara Rower Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,498 $135 $40–$426 $132
2022 $2,566 $152 $48–$470 $149
2023 $3,720 $166 $54–$529 $160
2024 $4,083 $173 $55–$556 $164
2025 $3,440 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,770 198 payments
  2. Janssen Biotech, Inc. $1,630 91 payments
  3. Lilly USA, LLC $1,327 76 payments
  4. Pfizer Inc. $1,193 69 payments
  5. Regeneron Healthcare Solutions, Inc. $1,047 68 payments
  6. UCB, Inc. $1,001 57 payments
  7. E.R. Squibb & Sons, L.L.C. $866 53 payments
  8. Novartis Pharmaceuticals Corporation $841 56 payments
  9. Genzyme Corporation $791 47 payments
  10. Incyte Corporation $716 50 payments
  11. Other $4,125 267 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,326 1,019 payments
  2. Education $980 13 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,343 61 payments
  2. TALTZ $1,313 75 payments
  3. DUPIXENT Immunology $1,193 68 payments
  4. SKYRIZI $1,124 91 payments
  5. CIBINQO $1,020 56 payments
  6. RINVOQ $843 58 payments
  7. SOTYKTU $820 50 payments
  8. DUPIXENT Inflammation And Immunology $786 40 payments
  9. EUCRISA $744 44 payments
  10. Bimzelx $739 40 payments
  11. Other $9,852 681 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

932

Median for Nurse Practitioner: 389

Drug cost

$110,919

Median for Nurse Practitioner: $21,885

Branded share of claims

1.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $81,216
Clobetasol Propionate Generic 73 $4,731
Fluorouracil Generic 28 $3,119
Gentamicin Sulfate Generic 59 $2,715
Metronidazole Generic 42 $2,658
Tacrolimus Generic 13 $2,494
Ketoconazole Generic 182 $2,451
Clindamycin Phosphate Generic 63 $2,409
Minocycline Hcl Generic 51 $2,150
Doxepin Hcl Generic 11 $1,338

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$107,804

Of which drugs: $58

Medicare patients

925

Average age 74

Services billed

2,999

551 women, 374 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 45%
Diabetes 28%
Ischemic heart disease 24%
Chronic kidney disease 20%
Depression 18%
Osteoporosis 16%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 87 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$462 — —
SKYRIZI
$283 — —
OPZELURA
$280 — —
Bimzelx
$264 — —
VTAMA
$249 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,032 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record